Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00814320 · ClinicalTrials.gov registry record · Phase 3
Gammagard Liquid and rHuPH20 in PID
A Phase 3 study, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 89
- Enrollment target
NCT00814320 is a Phase 3 study that has completed, run by Baxalta now part of Shire. The registered enrollment target is 89 participants.
The verdict
NCT00814320, a Phase 3 study, has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 89 participants
- Enrollment target
Study Summary
The purpose of the study is to develop a subcutaneous treatment option for participants with Primary Immunodeficiency Diseases (PID) that allows an administration of Immune Globulin Intravenous (Human), 10% at the same frequency as IV administration.
Interventions
- BIOLOGICAL Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2008-12-18 |
| Est. Completion | 2010-11-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00814320
The ClinicalTrials.gov registry entry for NCT00814320 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV) is the first listed.
NCT00814320 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00814320 about?
NCT00814320 is a clinical study titled "Gammagard Liquid and rHuPH20 in PID". The purpose of the study is to develop a subcutaneous treatment option for participants with Primary Immunodeficiency Diseases (PID) that allows an administration of Immune Globulin Intravenous (Human), 10% at the same frequency as IV administration.
What is the current status of trial NCT00814320?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 89 participants. The study started on 2008-12-18. Estimated completion is 2010-11-11.
What interventions are being tested in trial NCT00814320?
The interventions under investigation include: Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00814320?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.